Generator Activty
Generator Activty
Ultra-TechnekowTM FM
Mo-99/Tc-99m generator
Technetium-99m (activities for one elution per day)
Elution at 07:00 CET (in GBq)
Nominal activity in GBq 2,15 4,30 6,45 8,60 10,75 12,90 17,20 21,50 25,80 30,10 34,40 43,00 Nominal activity in GBq
ART -6 days 7,07 14,14 21,22 28,29 35,36 42,43 56,58 70,72 84,86 99,01 113,15 141,44 ART -6 days
ART -5 days 5,95 11,91 17,86 23,81 29,77 35,72 47,62 59,53 71,44 83,34 95,25 119,06 ART -5 days
ART -4 days 4,63 9,25 13,88 18,50 23,13 27,75 37,01 46,26 55,51 64,76 74,01 92,51 ART -4 days
ART -3 days 3,59 7,19 10,78 14,38 17,97 21,57 28,75 35,94 43,13 50,32 57,51 71,89 ART -3 days
ART -2 days 2,79 5,59 8,38 11,17 13,96 16,76 22,34 27,93 33,52 39,10 44,69 55,86 ART -2 days
ART -1 day 2,17 4,34 6,51 8,68 10,85 13,02 17,36 21,70 26,04 30,38 34,72 43,40 ART -1 day
ART 1,69 3,37 5,06 6,75 8,43 10,12 13,49 16,86 20,24 23,61 26,98 33,73 ART
ART +1 day 1,31 2,62 3,93 5,24 6,55 7,86 10,48 13,10 15,72 18,34 20,97 26,21 ART +1 day
ART +2 days 1,02 2,04 3,05 4,07 5,09 6,11 8,15 10,18 12,22 14,25 16,29 20,36 ART +2 days
ART +3 days 0,79 1,58 2,37 3,16 3,96 4,75 6,33 7,91 9,49 11,08 12,66 15,82 ART +3 days
ART +4 days 0,61 1,23 1,84 2,46 3,07 3,69 4,92 6,15 7,38 8,61 9,84 12,29 ART +4 days
ART +5 days 0,48 0,96 1,43 1,91 2,39 2,87 3,82 4,78 5,73 6,69 7,64 9,55 ART +5 days
ART +6 days 0,37 0,74 1,11 1,48 1,86 2,23 2,97 3,71 4,45 5,20 5,94 7,42 ART +6 days
ART +7 days 0,29 0,58 0,87 1,15 1,44 1,73 2,31 2,88 3,46 4,04 4,61 5,77 ART +7 days
Nominal activity in GBq 2,15 4,30 6,45 8,60 10,75 12,90 17,20 21,50 25,80 30,10 34,40 43,00 Nominal activity in GBq
07:00 7,07 14,14 21,22 28,29 35,36 42,43 56,58 70,72 84,86 99,01 113,15 141,44 07:00
ART -6 days ART -6 days
13:00 3,65 7,31 10,96 14,62 18,27 21,93 29,23 36,54 43,85 51,16 58,47 73,09 13:00
07:00 5,50 10,99 16,49 21,98 27,48 32,97 43,96 54,95 65,94 76,93 87,92 109,90 07:00
ART -5 days ART -5 days
13:00 2,84 5,68 8,52 11,36 14,20 17,04 22,72 28,39 34,07 39,75 45,43 56,79 13:00
07:00 4,27 8,54 12,81 17,08 21,35 25,62 34,16 42,70 51,24 59,78 68,32 85,40 07:00
ART -4 days ART -4 days
13:00 2,21 4,41 6,62 8,83 11,03 13,24 17,65 22,06 26,48 30,89 35,30 44,13 13:00
07:00 3,32 6,64 9,95 13,27 16,59 19,91 26,54 33,18 39,81 46,45 53,09 66,36 07:00
ART -3 days ART -3 days
13:00 1,71 3,43 5,14 6,86 8,57 10,29 13,72 17,14 20,57 24,00 27,43 34,29 13:00
07:00 2,58 5,16 7,73 10,31 12,89 15,47 20,62 25,78 30,94 36,09 41,25 51,56 07:00
ART -2 days ART -2 days
13:00 1,33 2,66 4,00 5,33 6,66 7,99 10,66 13,32 15,99 18,65 21,31 26,64 13:00
07:00 2,00 4,01 6,01 8,01 10,02 12,02 16,03 20,03 24,04 28,05 32,05 40,07 07:00
ART -1 day ART -1 day
13:00 1,04 2,07 3,11 4,14 5,18 6,21 8,28 10,35 12,42 14,49 16,56 20,70 13:00
07:00 1,56 3,11 4,67 6,23 7,78 9,34 12,45 15,57 18,68 21,79 24,91 31,13 07:00
ART ART
13:00 0,80 1,61 2,41 3,22 4,02 4,83 6,43 8,04 9,65 11,26 12,87 16,09 13:00
07:00 1,21 2,42 3,63 4,84 6,05 7,26 9,68 12,10 14,51 16,93 19,35 24,19 07:00
ART +1 day ART +1 day
13:00 0,62 1,25 1,87 2,50 3,12 3,75 5,00 6,25 7,50 8,75 10,00 12,50 13:00
07:00 0,94 1,88 2,82 3,76 4,70 5,64 7,52 9,40 11,28 13,16 15,04 18,80 07:00
ART +2 days ART +2 days
13:00 0,49 0,97 1,46 1,94 2,43 2,91 3,89 4,86 5,83 6,80 7,77 9,71 13:00
07:00 0,73 1,46 2,19 2,92 3,65 4,38 5,84 7,30 8,76 10,22 11,68 14,61 07:00
ART +3 days ART +3 days
13:00 0,38 0,75 1,13 1,51 1,89 2,26 3,02 3,77 4,53 5,28 6,04 7,55 13:00
07:00 0,57 1,13 1,70 2,27 2,84 3,40 4,54 5,67 6,81 7,94 9,08 11,35 07:00
ART +4 days ART +4 days
13:00 0,29 0,59 0,88 1,17 1,47 1,76 2,35 2,93 3,52 4,11 4,69 5,86 13:00
07:00 0,44 0,88 1,32 1,76 2,20 2,65 3,53 4,41 5,29 6,17 7,05 8,82 07:00
ART +5 days ART +5 days
13:00 0,23 0,46 0,68 0,91 1,14 1,37 1,82 2,28 2,73 3,19 3,65 4,56 13:00
07:00 0,34 0,69 1,03 1,37 1,71 2,06 2,74 3,43 4,11 4,80 5,48 6,85 07:00
ART +6 days ART +6 days
13:00 0,18 0,35 0,53 0,71 0,89 1,06 1,42 1,77 2,12 2,48 2,83 3,54 13:00
07:00 0,27 0,53 0,80 1,06 1,33 1,60 2,13 2,66 3,19 3,73 4,26 5,32 07:00
ART +7 days ART +7 days
13:00 0,14 0,28 0,41 0,55 0,69 0,83 1,10 1,38 1,65 1,93 2,20 2,75 13:00
Technetium-99m
Mo-99 activity at 06:00 CET (in GBq)
Nominal activity in GBq 2,15 4,30 6,45 8,60 10,75 12,90 17,20 21,50 25,80 30,10 34,40 43,00 Nominal activity in GBq
ART -6 days 9,77 19,54 29,30 39,07 48,84 58,61 78,14 97,68 117,22 136,75 156,29 195,36 ART -6 days
ART -5 days 7,59 15,18 22,77 30,36 37,95 45,54 60,72 75,90 91,08 106,26 121,44 151,80 ART -5 days
ART -4 days 5,90 11,80 17,69 23,59 29,49 35,39 47,18 58,98 70,77 82,57 94,36 117,95 ART -4 days
ART -3 days 4,58 9,17 13,75 18,33 22,91 27,50 36,66 45,83 54,99 64,16 73,32 91,65 ART -3 days
ART -2 days 3,56 7,12 10,68 14,24 17,80 21,37 28,49 35,61 42,73 49,85 56,97 71,22 ART -2 days
ART -1 day 2,77 5,53 8,30 11,07 13,83 16,60 22,14 27,67 33,20 38,74 44,27 55,34 ART -1 day
ART 2,15 4,30 6,45 8,60 10,75 12,90 17,20 21,50 25,80 30,10 34,40 43,00 ART
ART +1 day 1,67 3,34 5,01 6,68 8,35 10,02 13,36 16,71 20,05 23,39 26,73 33,41 ART +1 day
ART +2 days 1,30 2,60 3,89 5,19 6,49 7,79 10,38 12,98 15,58 18,17 20,77 25,96 ART +2 days
ART +3 days 1,01 2,02 3,03 4,03 5,04 6,05 8,07 10,09 12,10 14,12 16,14 20,17 ART +3 days
ART +4 days 0,78 1,57 2,35 3,14 3,92 4,70 6,27 7,84 9,41 10,97 12,54 15,68 ART +4 days
ART +5 days 0,61 1,22 1,83 2,44 3,05 3,65 4,87 6,09 7,31 8,53 9,74 12,18 ART +5 days
ART +6 days 0,47 0,95 1,42 1,89 2,37 2,84 3,79 4,73 5,68 6,63 7,57 9,46 ART +6 days
ART +7 days 0,37 0,74 1,10 1,47 1,84 2,21 2,94 3,68 4,41 5,15 5,88 7,35 ART +7 days
ART = Activity Reference Time | ART -7 days is production day | Tc-99m activities based on 89,5% average yield efficiency (standard error 0,03%)
Nominal activity in mCi 58 116 174 232 291 349 465 581 697 814 930 1162 Nominal activity in mCi
ART -6 days 191 382 573 765 956 1147 1529 1911 2294 2676 3058 3823 ART -6 days
ART -5 days 161 322 483 644 804 965 1287 1609 1931 2253 2574 3218 ART -5 days
ART -4 days 125 250 375 500 625 750 1000 1250 1500 1750 2000 2500 ART -4 days
ART -3 days 97 194 291 389 486 583 777 971 1166 1360 1554 1943 ART -3 days
ART -2 days 75 151 226 302 377 453 604 755 906 1057 1208 1510 ART -2 days
ART -1 day 59 117 176 235 293 352 469 587 704 821 938 1173 ART -1 day
ART 46 91 137 182 228 273 365 456 547 638 729 912 ART
ART +1 day 35 71 106 142 177 212 283 354 425 496 567 708 ART +1 day
ART +2 days 28 55 83 110 138 165 220 275 330 385 440 550 ART +2 days
ART +3 days 21 43 64 86 107 128 171 214 257 299 342 428 ART +3 days
ART +4 days 17 33 50 66 83 100 133 166 199 233 266 332 ART +4 days
ART +5 days 13 26 39 52 65 77 103 129 155 181 207 258 ART +5 days
ART +6 days 10 20 30 40 50 60 80 100 120 140 161 201 ART +6 days
ART +7 days 8 16 23 31 39 47 62 78 94 109 125 156 ART +7 days
Nominal activity in mCi 58 116 174 232 291 349 465 581 697 814 930 1162 Nominal activity in mCi
07:00 191 382 573 765 956 1147 1529 1911 2294 2676 3058 3823 07:00
ART -6 days ART -6 days
13:00 99 198 296 395 494 593 790 988 1185 1383 1580 1975 13:00
07:00 149 297 446 594 743 891 1188 1485 1782 2079 2376 2970 07:00
ART -5 days ART -5 days
13:00 77 153 230 307 384 460 614 767 921 1074 1228 1535 13:00
07:00 115 231 346 462 577 692 923 1154 1385 1616 1846 2308 07:00
ART -4 days ART -4 days
13:00 60 119 179 239 298 358 477 596 716 835 954 1193 13:00
07:00 90 179 269 359 448 538 717 897 1076 1255 1435 1793 07:00
ART -3 days ART -3 days
13:00 46 93 139 185 232 278 371 463 556 649 741 927 13:00
07:00 70 139 209 279 348 418 557 697 836 976 1115 1394 07:00
ART -2 days ART -2 days
13:00 36 72 108 144 180 216 288 360 432 504 576 720 13:00
07:00 54 108 162 217 271 325 433 541 650 758 866 1083 07:00
ART -1 day ART -1 day
13:00 28 56 84 112 140 168 224 280 336 392 448 560 13:00
07:00 42 84 126 168 210 252 337 421 505 589 673 841 07:00
ART ART
13:00 22 43 65 87 109 130 174 217 261 304 348 435 13:00
07:00 33 65 98 131 163 196 262 327 392 458 523 654 07:00
ART +1 day ART +1 day
13:00 17 34 51 68 84 101 135 169 203 236 270 338 13:00
07:00 25 51 76 102 127 152 203 254 305 356 406 508 07:00
ART +2 days ART +2 days
13:00 13 26 39 53 66 79 105 131 158 184 210 263 13:00
Technetium-99m
Mo-99 activity at 06:00 CET (in mCi)
Nominal activity in mCi 58 116 174 232 291 349 465 581 697 814 930 1162 Nominal activity in mCi
ART -6 days 264 528 792 1056 1320 1584 2112 2640 3168 3696 4224 5280 ART -6 days
ART -5 days 205 410 615 821 1026 1231 1641 2051 2462 2872 3282 4103 ART -5 days
ART -4 days 159 319 478 638 797 956 1275 1594 1913 2232 2550 3188 ART -4 days
ART -3 days 124 248 372 495 619 743 991 1239 1486 1734 1982 2477 ART -3 days
ART -2 days 96 192 289 385 481 577 770 962 1155 1347 1540 1925 ART -2 days
ART -1 day 75 150 224 299 374 449 598 748 897 1047 1197 1496 ART -1 day
ART 58 116 174 232 291 349 465 581 697 814 930 1162 ART
ART +1 day 45 90 135 181 226 271 361 452 542 632 722 903 ART +1 day
ART +2 days 35 70 105 140 175 211 281 351 421 491 561 702 ART +2 days
ART +3 days 27 55 82 109 136 164 218 273 327 382 436 545 ART +3 days
ART +4 days 21 42 64 85 106 127 169 212 254 297 339 424 ART +4 days
ART +5 days 16 33 49 66 82 99 132 165 198 230 263 329 ART +5 days
ART +6 days 13 26 38 51 64 77 102 128 153 179 205 256 ART +6 days
ART +7 days 10 20 30 40 50 60 80 99 119 139 159 199 ART +7 days
ART = Activity Reference Time | ART -7 days is production day | Tc-99m activities based on 89,5% average yield efficiency (standard error 0,03%)
Availability
l Production and shipment every working day
Range (activity in Mo-99): 2,15 / 4,30 / 6,45 / 8,60 / 10,75 / 12,90 / 17,20 / 21,50 / 25,80 / 30,10 / 34,40 / 43,00 GBq
l Activity Reference Time (ART): 7 days after production, 06:00 CET
l Expiry: 9 days after ART
Please consult your local Mallinckrodt representative to discuss our extensive distribution network.
Composition: A sterile generator containing the parent isotope 99Mo, adsorbed to an pregnancy. Radionuclide procedures carried out on pregnant women also involve
aluminium oxide column. The 99Mo on the column is in equilibrium with the formed radiation doses to the foetus. Only imperative investigations should be carried out
daughter isotope 99mTc. PHARMACEUTICAL FORM: Radionuclide generator. during pregnancy, when the likely benefit exceeds the risk incurred by the mother
THERAPEUTIC INDICATIONS: The eluate from the generator (Sodium Pertechnetate and the foetus. Before administering a radioactive medicinal product to a woman
(99mTc) Injection Ph. Eur.) may be used as a reagent for labelling of various carrier who is breast-feeding, consideration should be given as to whether the investigation
compounds supplied as kits or administered directly in-vivo. Indications include: could be reasonably delayed until the mother has ceased breast-feeding and as to
Thyroid scintigraphy; Salivary gland scintigraphy; Location of Meckel’s diverticulum; whether the most appropriate choice of radiopharmaceutical has been made. If the
Cerebral scintigraphy; Lacrimal duct scintigraphy: to assess patency of tear ducts. administration is considered necessary, breast-feeding should be interrupted for at
99
mTc-labelling of red blood cells: Cardiac and vascular scintigraphy; Diagnosis and least 12 hours and the expressed feeds discarded. Breast-feeding can be restarted
localisation of occult gastrointestinal bleeding. POSOLOGY AND METHOD OF when the activity level in the milk will not result in a radiation dose to the child
ADMINISTRATION: Sodium pertechnetate (99mTc) is normally administered greater than 1 mSv. UNDESIRABLE EFFECTS: Information on adverse reactions is
intravenously at activities which vary widely according to the clinical information available from spontaneous reporting. The reported reaction types are
required and the equipment employed. Pre-treatment of patients with thyroid anaphylactoid reactions, vegetative reactions, as well as different kinds of injection
blocking agents or reducing agents may be necessary for certain indications. site reactions. 99mTc-perchtechnetate from the Ultra-Technekow FM generator is
Children: The activity for administration to children may be calculated from the used for radioactive labeling of a variety of compounds. These pharmaceuticals
recommended range of adult activity and adjusted according to body weight or generally have a higher potential for side effects than 99mTc, and therefore the
surface area. CONTRA-INDICATIONS: Hypersensitivity to the active substance or any reported side effects are rather related to the labelled compounds than to 99mTc.
of the excipients. SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE: The possible types of side effects following intravenous administration of a 99mTc-
Radiopharmaceutical agents should be used only by qualified personnel with the labelled pharmaceutical preparation will be dependent on the specific compound
appropriate government authorizations for the use and manipulations of being used. Such information should be available from the manufacturer of the
radionuclides. INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER pharmaceutical which is to be radiolabelled. Exposure to ionising radiation is linked
FORMS OF INTERACTION: Drug interactions have been reported in brain with cancer induction and a potential for development of hereditary defects. For
scintigraphy where there can be increased uptake of (99mTc) pertechnetate in the diagnostic nuclear medicine investigations, the current evidence suggests that these
walls of cerebral ventricles as a result of methotrexate-induced ventriculitis. In adverse effects will occur with low frequency because of the low radiation doses
abdominal imaging drugs, such as atropine, isoprenaline and analgesics, can result in incurred. For most diagnostic investigations using a nuclear medicine procedure, the
a delay in gastric emptying and redistribution of pertechnetate. PREGNANCY AND radiation dose delivered is less than 20 mSv EDE. Higher doses may be justified in
LACTATION: 99mTc (as free pertechnetate) has been shown to cross the placental some clinical circumstances. This product contains no excipients that have a
barrier. When it is necessary to administer radioactive medicinal products to a recognised action or effect, or knowledge of which is important for safe and
woman of childbearing potential, information should always be sought about effective use of the product.
Product availability and Summary of Product Characteristics may differ from one country to another.
For your country’s specific information, please contact your local Mallinckrodt Office or Representative.
CURIUM
MALLINCKRODT MEDICAL B.V.
P.O. Box 3, 1755 ZG Petten, the Netherlands